FibroScan受控衰减参数与肝脏硬度测量评估非酒精性脂肪性肝病患者脂肪变性与纤维化的准确性
研究纳入英国7中心450例连续接受肝活检的疑似非酒精性脂肪性肝病(NAFLD)成人,评估FibroScan受控衰减参数(CAP)和肝脏硬度测量(LSM)的诊断准确性;CAP诊断脂肪变性的AUROC为0.70-0.87,LSM诊断纤维化的AUROC为0.77-0.89,探针类型和脂肪变性未影响LSM。
要点
- CAP诊断脂肪变性S≥S1、S≥S2、S=S3的AUROC分别为0.87、0.77、0.70。
- LSM诊断纤维化F≥F2、F≥F3、F=F4的AUROC分别为0.77、0.80、0.89。
- 多因素分析显示仅纤维化分期显著影响LSM(P<10-16),脂肪变性和探针类型无关联。
核心结论
- 在NAFLD患者的前瞻性分析中,FibroScan的CAP和LSM分别评估肝脏脂肪变性和纤维化,AUROC值为0.70至0.89。
- 探针类型和脂肪变性未影响LSM。
研究设计与样本
- 研究收集了2014年3月至2017年1月在英国7个中心连续接受肝活检分析以评估疑似NAFLD的450例成人数据。
- FibroScan检查(使用M或XL探针)在活检分析后2周内完成,404例有有效检查。
- 活检由2名盲法专家病理学家根据非酒精性脂肪性肝炎临床研究网络标准进行评分。
- 诊断准确性使用受试者工作特征曲线下面积(AUROC)评估脂肪变性和纤维化类别。
- 研究评估了疾病患病率对阳性和阴性预测值的影响,并使用多因素分析评估组织学参数和探针类型对LSM的影响。
主要发现
- 以活检分析为参考标准,CAP识别脂肪变性患者的AUROC为:S≥S1为0.87(95%CI 0.82-0.92),S≥S2为0.77(95%CI 0.71-0.82),S=S3为0.70(95%CI 0.64-0.75)。
- S≥S1、S≥S2和S≥S3的约登截断值分别为302 dB/m、331 dB/m和337 dB/m。
- LSM识别纤维化患者的AUROC为:F≥F2为0.77(95%CI 0.72-0.82),F≥F3为0.80(95%CI 0.75-0.84),F=F4为0.89(95%CI 0.84-0.93)。
- F≥F2、F≥F3和F=F4的约登截断值分别为8.2 kPa、9.7 kPa和13.6 kPa。
- 将本队列确定的最佳截断值应用于较低纤维化患病率人群,阴性预测值增加而阳性预测值降低。
关键数值与推荐
- CAP诊断脂肪变性S≥S1的AUROC为0.87(95%CI 0.82-0.92),约登截断值为302 dB/m。
- CAP诊断脂肪变性S≥S2的AUROC为0.77(95%CI 0.71-0.82),约登截断值为331 dB/m。
- CAP诊断脂肪变性S=S3的AUROC为0.70(95%CI 0.64-0.75),约登截断值为337 dB/m。
- LSM诊断纤维化F≥F2的AUROC为0.77(95%CI 0.72-0.82),约登截断值为8.2 kPa。
- LSM诊断纤维化F≥F3的AUROC为0.80(95%CI 0.75-0.84),约登截断值为9.7 kPa;F=F4的AUROC为0.89(95%CI 0.84-0.93),约登截断值为13.6 kPa。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We estimated the accuracy of FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and fibrosis in patients with suspected nonalcoholic liver disease (NAFLD). METHODS: We collected data from 450 consecutive adults who underwent liver biopsy analysis for suspected NAFLD at 7 centers in the United Kingdom from March 2014 through January 2017. FibroScan examinations with M or XL probe were completed within the 2 weeks of the biopsy analysis (404 had a valid examination). The biopsies were scored by 2 blinded expert pathologists according to nonalcoholic steatohepatitis clinical research network criteria. Diagnostic accuracy was estimated using the area under the receiver operating characteristic curves (AUROCs) for the categories of steatosis and fibrosis. We assessed effects of disease prevalence on positive and negative predictive values. For LSM, the effects of histological parameters and probe type were appraised using multivariable analysis. RESULTS: Using biopsy analysis as the reference standard, we found that CAP identified patients with steatosis with an AUROC of 0.87 (95% confidence interval [CI] 0.82-0.92) for S≥S1, 0.77 (95% CI 0.71-0.82) for S≥S2, and 0.70 (95% CI 0.64-0.75) for S=S3. Youden cutoff values for S≥S1, S≥S2, and S≥S3 were 302 dB/m, 331 dB/m, and 337 dB/m, respectively. LSM identified patients with fibrosis with AUROCs of 0.77 (95% CI 0.72-0.82) for F≥F2, 0.80 (95% CI 0.75-0.84) for F≥F3, and 0.89 (95% CI 0.84-0.93) for F=F4. Youden cutoff values for F≥F2, F≥F3, and F=F4 were 8.2 kPa, 9.7 kPa, and 13.6 kPa, respectively. Applying the optimal cutoff values, determined from this cohort, to populations of lower fibrosis prevalence increased negative predictive values and reduced positive predictive values. Multivariable analysis found that the only parameter that significantly affected LSMs was fibrosis stage (P<10-16); we found no association with steatosis or probe type. CONCLUSIONS: In a prospective analysis of patients with NAFLD, we found CAP and LSM by FibroScan to assess liver steatosis and fibrosis, respectively, with AUROC values ranging from 0.70 to 0.89. Probe type and steatosis did not affect LSM. STUDY REGISTRATION: ClinicalTrials.gov Identifier: NCT01985009.
引用
- Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019. PMID: 30689971. doi:10.1053/j.gastro.2019.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。